THORASYS SHIPS ITS FIRST SYSTEM FOR NEWBORN INVESTIGATIONAL TESTS
The tremoflo N-100, the ideal device for testing babies
Montreal, January 20, 2020 – It is with enthusiasm that we are making the tremoflo N-100 available for research purpose for the study of respiratory function in toddlers, especially from their very first days.
The tremoflo N-100 is an investigational medical device that uses a forced wave oscillometry system, an innovative technology in the respiratory field. The technique allows for rapid measurements of the lung condition and with less effort than spirometers. The contribution of tremoflo N-100 in assessing respiratory function in relation to treatment or changes in health conditions may prove to be important in pulmonary studies, because no other similar techniques or tests are currently available. Yvan Beaudoin, President and CEO of Thorasys, is delighted with this scientific advance: “With the tremoflo N-100, we are continuing to develop our oscillometry technology for different types of studies.”
Some researchers affiliated with children’s hospitals already have the tremoflo N-100 in their possession to assess the impact of the device. The first to conduct a clinical study with it is Dr. Ambalavanan in Alabama. Here in Quebec, under the FISSS research program, Dr. Lands at the McGill University Healthcare Center will be the first Canadian to use it: “It is great that a Quebec company is leading the way forward in developing this technology for use across the lifespan. This will be important clinical information with respect to Canadian children, where about 1 in 10 children have asthma, and 1 in 5 new cases are caused by traffic pollution.” Other researchers in the neonatal respiratory sector such as Dr. Tepper in Indianapolis and Dr. Moschovis at Harvard University in Boston are also using the tremoflo N-100 in clinical studies.
Dr. Lennart Lundblad, Director of Clinical Science at Thorasys, is very happy to be one of those who contributed to the N-100 tremoflo project: “Assessing the lung health of babies is difficult but with the tremoflo N-100 this is now possible and will help clinicians to establish correlations between lung function changes and disease towards better treatments for our most vulnerable patients. There is a huge interest in this new device, and we are working with world leaders in pediatrics to establish this new technique.”
Thorasys is a small medium-sized enterprise (SME), based in Montreal, Quebec, Canada, which designs, manufactures and markets respiratory medical devices. Thorasys applies state-of-the-art research and technology in the development of products for the assessment and monitoring of lung diseases such as asthma, COPD and cystic fibrosis.
Eve-Gabrielle Bissonnette, Marketing Manager